Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

101. Chronic kidney disease - not diabetic

Chronic kidney disease - not diabetic Chronic kidney disease - not diabetic - NICE CKS Clinical Knowledge Summaries Share Chronic kidney disease - not diabetic - Summary Chronic kidney disease (CKD) is an abnormality of kidney function or structure that is present for more than 3 months, with implications for health. Complications of CKD include worsening renal disease that progresses to renal replacement therapy, cardiovascular disease, renal anaemia, renal bone disease, malnutrition (...) hypertension. Suspected renal artery stenosis. A rare genetic cause of CKD. Complications such as anaemia or renal bone disease. Have I got the right topic? Age from 18 years onwards This CKS topic is based on the National Institute for Health and Care Excellence (NICE) guideline, Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care [ ]. This CKS topic covers the identification and management of chronic kidney disease in adults

NICE Clinical Knowledge Summaries2016

102. What Is the Significance of Elevated Troponin in Patients With Suspected Acute Coronary Syndrome and Chronic Kidney Disease?

What Is the Significance of Elevated Troponin in Patients With Suspected Acute Coronary Syndrome and Chronic Kidney Disease? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2016

104. ERBP Guideline on Management of Older Patients with Chronic Kidney Disease

ERBP Guideline on Management of Older Patients with Chronic Kidney Disease Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m2) | Nephrology Dialysis Transplantation | Oxford Academic We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Search Account Menu Menu Navbar Search Filter Mobile (...) Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation November 2016 Article Contents Article Navigation Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m 2 ) Ken Farrington Search for other works by this author on: Adrian Covic Search for other works by this author on: Fillipo Aucella Search for other works by this author on: Naomi Clyne Search for other

European Renal Best Practice2016

105. Decision Support for Adults Living with Chronic Kidney Disease

Decision Support for Adults Living with Chronic Kidney Disease Decision Support for Adults Living with Chronic Kidney Disease | Registered Nurses' Association of Ontario l’Association des infirmières et infirmiers autorisés de l’Ontario Speaking out for nursing. Speaking out for health. » » Decision Support for Adults Living with Chronic Kidney Disease Type of Guideline: Clinical Status: Published Publish Date: 2009 About this Guideline : The purpose of this best practice guideline is: To help (...) nurses recognize patients with CKD experiencing decisional conflict related to situations in which there is more than one option available for managing their condition. To help nurses support patient involvement in reaching quality health decisions. Quality decisions are made using the best available evidence about the options and are consistent with the patients’ values. Clinical questions addressed in the guideline include: What are the common health decisions faced by patients with CKD? How can

Registered Nurses' Association of Ontario2016

106. Systematic review with meta analysis: Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes

Systematic review with meta analysis: Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use (...) of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has

Evidence-Based Medicine (Requires free registration)2016

107. Sucroferric oxyhydroxide (Velphoro) - for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD)

Sucroferric oxyhydroxide (Velphoro) - for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD) %PDF-1.5 %���� 37 0 obj > endobj 52 0 obj >/Filter/FlateDecode/ID[ ]/Index[37 24]/Info 36 0 R/Length 78/Prev 97882/Root 38 0 R/Size 61/Type/XRef/W[1 2 1]>>stream h�bbd``b`j�S@D�`� A�U�l7��e������X�@�+�R7���Y �����;�. endstream endobj startxref 0 %%EOF 60 0 obj >stream h�b``�e``*e```L;̀ �����Y������?�6 (...) �I8����y�٤�+��9y򃋖�'������ k��Q��O_ �G�{�� �p��`����*�H�R>T�)P^��(Mg����h�����@Ni��2�����lfG%A�"K9��yZVJ/��B��F� ���p�� �wSȤ3bZ��}��lEa��K�a�a �ʇ��0���K�� �0%�Q�*a�ώ��g�=#bZ�+����B����1?�~dK��n�6��&�Y�\r�=�GP\�|��_X���)�"�\ĵ���� �����/ܱ��=������ a5�ƒ��&6���խm�پ2�&��f��s۽)���4� 7�s����r?R��# ��Ū��Ej"zMĠ��5C��MXW{��7���'��4{֎����Kͦ�'�'{�^wu.���`kO�:�6�䶄��I8:rؼ�:���>}��-MS��q�c5OX�!�5Ne5a1^=f����A�~`����9l������a�^{I�c�+�H:��v21�)��bj�uZL�y0D��y3� 7�iQ���)����Z�n����YB�c ?�x��Oa�ps�������;��l

All Wales Medicines Strategy Group2015

108. A suPAR Biomarker for Chronic Kidney Disease.

A suPAR Biomarker for Chronic Kidney Disease. A suPAR Biomarker for Chronic Kidney Disease. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26539740 Format MeSH and Other Data E-mail Subject Additional text E (...) -mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Nov 12;373(20):1971-2. doi: 10.1056/NEJMe1512997. Epub 2015 Nov 5. A suPAR Biomarker for Chronic Kidney Disease. 1 , . 1 From the Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Rambam Health Care Campus, Haifa, Israel (K.L.S.); and the Department of Internal Medicine, Section on Nephrology, Wake Forest School

NEJM2015

109. Soluble Urokinase Receptor and Chronic Kidney Disease.

Soluble Urokinase Receptor and Chronic Kidney Disease. BACKGROUND: Relatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) have been associated with focal segmental glomerulosclerosis and poor clinical outcomes in patients with various conditions. It is unknown whether elevated suPAR levels in patients with normal kidney function are associated with future decline in the estimated glomerular filtration rate (eGFR) and with incident chronic kidney disease (...) . METHODS: We measured plasma suPAR levels in 3683 persons enrolled in the Emory Cardiovascular Biobank (mean age, 63 years; 65% men; median suPAR level, 3040 pg per milliliter) and determined renal function at enrollment and at subsequent visits in 2292 persons. The relationship between suPAR levels and the eGFR at baseline, the change in the eGFR over time, and the development of chronic kidney disease (eGFR <60 ml per minute per 1.73 m(2) of body-surface area) were analyzed with the use of linear

NEJM2015

110. The double challenge of resistant hypertension and chronic kidney disease.

The double challenge of resistant hypertension and chronic kidney disease. Resistant hypertension is defined as blood pressure above goal despite adherence to a combination of at least three optimally dosed antihypertensive medications, one of which is a diuretic. Chronic kidney disease is the most frequent of several patient factors or comorbidities associated with resistant hypertension. The prevalence of resistant hypertension is increased in patients with chronic kidney disease, while (...) chronic kidney disease is associated with an impaired prognosis in patients with resistant hypertension. Recommended low-salt diet and triple antihypertensive drug regimens that include a diuretic, should be complemented by the sequential addition of other antihypertensive drugs. New therapeutic innovations for resistant hypertension, such as renal denervation and carotid barostimulation, are under investigation especially in patients with advanced chronic kidney disease. We discuss resistant

Lancet2015

111. Evaluation of Rhubarb Supplementation in Stages 3 and 4 of Chronic Kidney Disease: A Randomized Clinical Trial.

Evaluation of Rhubarb Supplementation in Stages 3 and 4 of Chronic Kidney Disease: A Randomized Clinical Trial. 26464863 2015 10 14 2015 10 14 2017 02 20 2356-6981 2014 2014 International journal of chronic diseases Int J Chronic Dis Evaluation of Rhubarb Supplementation in Stages 3 and 4 of Chronic Kidney Disease: A Randomized Clinical Trial. 789340 10.1155/2014/789340 Objective. To evaluate the efficacy and safety of Rhubarb supplementation in patients of chronic kidney disease. Material (...) and Methods. This study was a prospective comparative study conducted in patients of chronic kidney disease (stages 3 & 4) attending Renal Clinic of Department of Medicine, JN Medical College & Hospital, AMU, Aligarh. Patients were randomly divided into two interventional groups. Group I (Control) was given conservative management while Group II (Rhubarb) received conservative management along with Rhubarb capsule (350 mg, thrice daily) for 12 weeks. Haemogram and renal function tests were measured at 0

International journal of chronic diseases2015 Full Text: Link to full Text with Trip Pro

112. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. BACKGROUND: Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronic kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C and chronic kidney disease have few treatment options. This study assesses an all-oral, ribavirin (...) -free regimen in patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease. METHODS: In this phase 3 randomised study of safety and observational study of efficacy, patients with HCV genotype 1 infection and chronic kidney disease (stage 4-5 with or without haemodialysis dependence) were randomly assigned to receive grazoprevir (100 mg, NS3/4A protease inhibitor) and elbasvir (50 mg, NS5A inhibitor; immediate treatment group) or placebo (deferred treatment group) once daily for 12

Lancet2015

113. A Positive Association Between Periodontal Disease and Chronic Kidney Disease is Evident, But Periodontal Treatment Effects Unknown

A Positive Association Between Periodontal Disease and Chronic Kidney Disease is Evident, But Periodontal Treatment Effects Unknown UTCAT2938, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title A Positive Association Between Periodontal Disease and Chronic Kidney Disease is Evident, But Periodontal Treatment Effects Unknown Clinical Question In patients with chronic kidney disease, does periodontal treatment improve (...) kidney function (estimated glomerular filtration rate (eGFR))? Clinical Bottom Line Periodontal disease and chronic kidney disease share similar risk factors (smoking, impaired wound healing, diabetes mellitus, malnutrition, and poor oral hygiene) and a positive association between the two diseases has been shown. Intervention studies offer limited and inconsistent evidence for improvement following periodontal treatment in patients with CKD and periodontitis. No adverse outcomes were seen

UTHSCSA Dental School CAT Library2015

115. Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions

Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions 26112195 2015 06 26 2015 09 10 2016 02 18 1558-3597 65 25 2015 Jun 30 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Choice of Estimated Glomerular Filtration Rate Equation Impacts Drug-Dosing Recommendations and Risk Stratification in Patients With Chronic Kidney Disease (...) Undergoing Percutaneous Coronary Interventions. 2714-23 10.1016/j.jacc.2015.04.037 S0735-1097(15)02064-1 Multiple equations exist to estimate glomerular filtration rate (GFR); however, there is no consensus on which is superior for risk classification in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI). The goals of this study were to identify which equation to estimate GFR is superior for predicting adverse outcomes after PCI and to examine how equation

EvidenceUpdates2015

116. Chronic kidney disease.

Chronic kidney disease. This issue provides a clinical overview of chronic kidney disease, focusing on prevention, diagnosis, treatment, and patient information. The content of In the Clinic is drawn from the clinical information and education resources of the American College of Physicians (ACP), including ACP Smart Medicine and MKSAP (Medical Knowledge and Self-Assessment Program). Annals of Internal Medicine editors develop In the Clinic from these primary sources in collaboration

Annals of Internal Medicine2015

117. Sucroferric oxyhydroxide (Velphoro) - For the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD)

Sucroferric oxyhydroxide (Velphoro) - For the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD)

Scottish Medicines Consortium2015